Theriva Gross Profit from 2010 to 2025

TOVX Stock

USD 1.47 0.15 9.26%

Theriva Biologics Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit is likely to outpace its year average in 2025. Gross Profit is the profit Theriva Biologics makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

1993-03-31

Previous Quarter

-39 K

Current Value

-38 K

Quarterly Volatility

344 K

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Theriva Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Theriva Biologics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 101.5 K, Total Revenue of 0.0 or Other Operating Expenses of 13.9 M, as well as many indicators such as Price To Sales Ratio of 241, Dividend Yield of 0.0 or PTB Ratio of 0.19. Theriva financial statements analysis is a perfect complement when working with Theriva Biologics Valuation or Volatility modules.

Check out the analysis of Theriva Biologics Correlation against competitors.

For more information on how to buy Theriva Stock please use our How to Invest in Theriva Biologics guide.

Latest Theriva Biologics' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Theriva Biologics over the last few years. Gross profit is a required income statement account that reflects total revenue of Theriva Biologics minus its cost of goods sold. It is profit before Theriva Biologics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Theriva Biologics' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Theriva Biologics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 0

10 Years Trend

Very volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Theriva Gross Profit Regression Statistics

	Arithmetic Mean	(186,745)
	Coefficient Of Variation	(51.09)
	Mean Deviation	71,850
	Median	(240,000)
	Standard Deviation	95,402
	Sample Variance	9.1B
	Range	368K
	R-Value	0.04
	Mean Square Error	9.7B
	R-Squared	0
	Significance	0.90
	Slope	703.13
	Total Sum of Squares	136.5B

Theriva Gross Profit History

	2025	-115.4 K
	2024	-121.5 K
	2023	-135 K
	2022	-268 K
	2021	-87 K
	2020	-201 K

Other Fundumenentals of Theriva Biologics

Gross Profit Margin

Theriva Biologics Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Net Receivables	Short Term Investments	Intangible Assets	Common Stock	Good Will	Net Tangible Assets	Net Invested Capital	Capital Stock	Net Working Capital	Property Plant Equipment	Long Term Debt	Deferred Long Term Liab	Short Long Term Debt	Current Deferred Revenue
Total Assets		0.95	-0.73	-0.77	-0.02	0.53	0.87	0.62	0.59	-0.36	0.46	-0.33	0.77	0.93	0.89	-0.93	0.57	0.89	-0.6	-0.5	0.57	-0.5
Total Stockholder Equity	0.95		-0.77	-0.7	-0.19	0.23	0.87	0.49	0.51	-0.3	0.38	-0.35	0.67	0.9	0.89	-0.92	0.62	0.86	-0.51	-0.42	0.48	-0.42
Net Debt	-0.73	-0.77		0.54	-0.01	-0.2	-0.96	0.04	0.04	0.31	-0.29	0.05	-0.15	-0.66	-0.79	0.61	-0.84	-0.58	-0.03	-0.04	0.03	-0.04
Retained Earnings	-0.77	-0.7	0.54		-0.14	-0.54	-0.64	-0.58	-0.5	0.51	-0.57	0.51	-0.61	-0.57	-0.51	0.74	-0.11	-0.69	0.51	0.33	-0.46	0.33
Accounts Payable	-0.02	-0.19	-0.01	-0.14		0.5	0.08	-0.09	-0.16	-0.23	0.2	0.0	-0.15	-0.24	-0.25	0.24	-0.18	-0.19	0.13	0.06	-0.11	0.06
Total Liab	0.53	0.23	-0.2	-0.54	0.5		0.35	0.55	0.43	-0.33	0.41	-0.12	0.55	0.4	0.32	-0.39	0.06	0.4	-0.46	-0.39	0.44	-0.39
Total Current Assets	0.87	0.87	-0.96	-0.64	0.08	0.35		0.17	0.19	-0.37	0.4	-0.15	0.35	0.79	0.85	-0.74	0.79	0.7	-0.2	-0.19	0.19	-0.19
Short Term Debt	0.62	0.49	0.04	-0.58	-0.09	0.55	0.17		0.83	-0.25	0.39	-0.54	0.95	0.54	0.38	-0.65	-0.18	0.64	-0.82	-0.6	0.73	-0.6
Net Receivables	0.59	0.51	0.04	-0.5	-0.16	0.43	0.19	0.83		-0.2	0.38	-0.39	0.87	0.65	0.4	-0.69	-0.07	0.63	-0.99	-0.79	0.92	-0.79
Short Term Investments	-0.36	-0.3	0.31	0.51	-0.23	-0.33	-0.37	-0.25	-0.2		-0.96	0.79	-0.18	-0.17	-0.16	0.22	0.0	-0.24	0.19	0.11	-0.22	0.11
Intangible Assets	0.46	0.38	-0.29	-0.57	0.2	0.41	0.4	0.39	0.38	-0.96		-0.82	0.34	0.29	0.19	-0.33	0.02	0.29	-0.36	-0.36	0.35	-0.36
Common Stock	-0.33	-0.35	0.05	0.51	0.0	-0.12	-0.15	-0.54	-0.39	0.79	-0.82		-0.42	-0.13	-0.04	0.27	0.27	-0.27	0.36	0.27	-0.33	0.27
Good Will	0.77	0.67	-0.15	-0.61	-0.15	0.55	0.35	0.95	0.87	-0.18	0.34	-0.42		0.74	0.59	-0.81	0.06	0.79	-0.87	-0.69	0.81	-0.69
Net Tangible Assets	0.93	0.9	-0.66	-0.57	-0.24	0.4	0.79	0.54	0.65	-0.17	0.29	-0.13	0.74		0.94	-0.94	0.68	0.89	-0.65	-0.53	0.61	-0.53
Net Invested Capital	0.89	0.89	-0.79	-0.51	-0.25	0.32	0.85	0.38	0.4	-0.16	0.19	-0.04	0.59	0.94		-0.88	0.79	0.89	-0.41	-0.25	0.4	-0.25
Capital Stock	-0.93	-0.92	0.61	0.74	0.24	-0.39	-0.74	-0.65	-0.69	0.22	-0.33	0.27	-0.81	-0.94	-0.88		-0.49	-0.93	0.68	0.51	-0.63	0.51
Net Working Capital	0.57	0.62	-0.84	-0.11	-0.18	0.06	0.79	-0.18	-0.07	0.0	0.02	0.27	0.06	0.68	0.79	-0.49		0.44	0.07	-0.04	-0.06	-0.04
Property Plant Equipment	0.89	0.86	-0.58	-0.69	-0.19	0.4	0.7	0.64	0.63	-0.24	0.29	-0.27	0.79	0.89	0.89	-0.93	0.44		-0.66	-0.35	0.66	-0.35
Long Term Debt	-0.6	-0.51	-0.03	0.51	0.13	-0.46	-0.2	-0.82	-0.99	0.19	-0.36	0.36	-0.87	-0.65	-0.41	0.68	0.07	-0.66		0.78	-0.95	0.78
Deferred Long Term Liab	-0.5	-0.42	-0.04	0.33	0.06	-0.39	-0.19	-0.6	-0.79	0.11	-0.36	0.27	-0.69	-0.53	-0.25	0.51	-0.04	-0.35	0.78		-0.76	1.0
Short Long Term Debt	0.57	0.48	0.03	-0.46	-0.11	0.44	0.19	0.73	0.92	-0.22	0.35	-0.33	0.81	0.61	0.4	-0.63	-0.06	0.66	-0.95	-0.76		-0.76
Current Deferred Revenue	-0.5	-0.42	-0.04	0.33	0.06	-0.39	-0.19	-0.6	-0.79	0.11	-0.36	0.27	-0.69	-0.53	-0.25	0.51	-0.04	-0.35	0.78	1.0	-0.76

Click cells to compare fundamentals

About Theriva Biologics Financial Statements

Theriva Biologics investors use historical fundamental indicators, such as Theriva Biologics' Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Theriva Biologics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Gross Profit	-121.5 K	-115.4 K
Gross Profit Margin	0.77	0.63

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin

Additional Tools for Theriva Stock Analysis

When running Theriva Biologics' price analysis, check to measure Theriva Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theriva Biologics is operating at the current time. Most of Theriva Biologics' value examination focuses on studying past and present price action to predict the probability of Theriva Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theriva Biologics' price. Additionally, you may evaluate how the addition of Theriva Biologics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC